Adrenocortical Carcinoma

Baudin, Éric

doi:10.1016/j.ecl.2015.03.001

Cited by 56 publications

(49 citation statements)

References 129 publications

(206 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACC is a rare malignancy occurring in about 0.7-2.0 cases per million population per year, and is responsible for 0.2% of all cancer deaths in the United States [ 26 ]. Currently, the main curative treatment for ACC is surgery, with an overall 5-year survival rate for all patients undergoing tumor resection of approximately 40% [ 27 - 29 ]. Surgery for removal of recurrent tumor, including metastatic lesions can also prolong survival ([ 26 ] and unpublished data).…”

Section: Introductionmentioning

confidence: 99%

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET

et al. 2017

View full text Add to dashboard Cite

Expression of the chemokine receptor CXCR4 by many cancers correlates with aggressive clinical behavior. As part of the initial studies in a project whose goal was to quantify CXCR4 expression on cancers non-invasively, we examined CXCR4 expression in cancer samples by immunohistochemistry using a validated anti-CXCR4 antibody. Among solid tumors, we found expression of CXCR4 on significant percentages of major types of kidney, lung, and pancreatic adenocarcinomas, and, notably, on metastases of clear cell renal cell carcinoma and squamous cell carcinoma of the lung. We found particularly high expression of CXCR4 on adrenocortical cancer (ACC) metastases. Microarrays of ACC metastases revealed correlations between expression of CXCR4 and other chemokine system genes, particularly CXCR7/ACKR3, which encodes an atypical chemokine receptor that shares a ligand, CXCL12, with CXCR4. A first-in-human study using 64Cu-plerixafor for PET in an ACC patient prior to resection of metastases showed heterogeneity among metastatic nodules and good correlations among PET SUVs, CXCR4 staining, and CXCR4 mRNA. Additionally, we were able to show that CXCR4 expression correlated with the rates of growth of the pulmonary lesions in this patient. Further studies are needed to understand better the role of CXCR4 in ACC and whether targeting it may be beneficial. In this regard, non-invasive methods for assessing CXCR4 expression, such as PET using 64Cu-plerixafor, should be important investigative tools.

show abstract

Section: Introductionmentioning

confidence: 99%

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Overall survival was defined as the time interval between the date of treatment start and the date of death from any cause or the last known alive date. The mENSAT classification and GRAS parameters (22), as defined by grade (Weiss score <6 or >6 or Ki67 <20% or >20%), resection status of the primary, age younger than or older than 50 years, and absence or presence of tumor related or hormone-related symptoms at diagnosis, were used to assess prognosis. The CTCAE v4.03 score was used to assess toxicity.…”

Section: Study Design and Patient Characteristicsmentioning

confidence: 99%

Activity and safety of temozolomide in advanced adrenocortical carcinoma patients

Cosentini

Badalamenti

Grisanti

et al. 2019

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro. Design On the basis of these results the drug was prescribed as second/third line in advanced metastatic ACC patients in four referral centers in Italy. Methods We retrospectively collected anagraphic, clinical and pathological data of patients with advanced ACC with disease progression to standard chemotherapy plus mitotane who were treated with temozolomide at the dose of 200 mg/m2/die given for 5 consecutive days every 28 days. The primary endpoint was the disease control rate, defined as objective response or disease stabilization after 3 months. Secondary endpoints were overall survival (OS), progression-free survival (PFS) and drug safety. Results Twenty-eight patients have been included in the study. Ten patients (35.8%, 95% CI: 17.8–53.8) obtained a disease control from temozolomide treatment. In particular, 1 patient had a complete response, 5 patients a partial response and 4 patients stable disease. Median PFS was 3.5 months and median OS was 7.2 months. Disease response was more frequently observed in patients with methylation of O6-methylguanine-DNA methyltransferase (MGMT) gene. Temozolomide therapy was well tolerated and most toxicities were limited to grade G1–2 according to WHO criteria. Conclusion Temozolomide was found active in the management of advanced ACC patients. The disease control rate obtained, however, was short-lived and the prognosis of treated patients was poor.

show abstract

“…Adrenocortical carcinoma (ACC) is an uncommon and heterogeneous endocrine malignant neoplasm with an estimated incidence of 0.5–2.0 cases per million per year (12). It usually occurs in adults with a peak incidence in the fifth decade of life; females are more commonly affected than males (3).…”

Section: Introductionmentioning

confidence: 99%

“…Patients with ACC generally show an unfavorable prognosis and a marked inter-individual variability in disease progression, recurrence, and overall survival (12). Because of the difficulty in differentiating the benign from malignant adrenocortical tumors, various multi-parametric diagnostic algorithms, such as the Weiss, Hough, van Slooten, modified Weiss scoring systems, and reticulin algorithm, have been used (3132).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Myxoid and Sarcomatoid Variants of Adrenocortical Carcinoma: Analysis of Rare Variants in Single Tertiary Care Center

et al. 2017

View full text Add to dashboard Cite

The aim of this study is to describe rare variants of adrenocortical carcinoma (ACC) and to compare the prognosis with that of conventional ACC. We retrospectively reviewed 8 cases of myxoid variant, 1 sarcomatoid variant, and 14 cases of conventional ACC, who underwent surgical resection at the Asan Medical Center between 1996 and 2014. An analysis of the clinicopathological characteristics, including the Weiss score, Ki-67 labeling index, and reticulin framework assessment is presented. The mean age of patients with myxoid/sarcomatoid ACC was 45 years; 4 out of 9 patients were women. Mean primary tumor size was 12.9 cm and the mean weight was 702.4 g. Seven patients presented in an advanced stage (stage III/IV); 8 of these eventually developed distant metastasis. The mean Weiss score was 5.0 points and the Ki-67 labeling index was 15.6%. The extent of myxoid or sarcomatoid change on histological examination ranged from 10% to 75% of the examined tumor areas; reticulin framework alteration was observed in all cases. Four patients showed venous tumor thrombus. Most of the clinicopathological parameters were not significantly different from those of conventional ACC. However, myxoid or sarcomatoid variant (hazard ratios [HR], 3.59; 95% confidence intervals [CI], 1.13–11.38; P = 0.030) and Ki-67 labeling index (HR, 3.97; 95% CI, 1.18–13.41; P = 0.030) were independent predictors of overall survival after adjusting for age and sex. Myxoid or sarcomatoid histological features or an increased Ki-67 labeling index may be associated with poor overall survival in patients with ACC.

show abstract

Adrenocortical Carcinoma

Cited by 56 publications

References 129 publications

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET

Activity and safety of temozolomide in advanced adrenocortical carcinoma patients

Myxoid and Sarcomatoid Variants of Adrenocortical Carcinoma: Analysis of Rare Variants in Single Tertiary Care Center

Contact Info

Product

Resources

About